Skip to main content
TOVX
NYSE Life Sciences

Theriva 10-Q Reaffirms Going Concern: $8.5M Cash Lasts Only Into Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.16
Mkt Cap
$7.384M
52W Low
$0.136
52W High
$0.492
52W Position info
18% above low
Off High info
67% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

TOVX sits 18% above its 52-week low of $0.136 on light trading volume (0.3× avg).

Summary

Theriva's Q3 10-Q shows a narrower $1.5 million loss and $8.5 million of cash, but management reaffirms substantial doubt about going concern with runway only into Q1 2027 — before the Q3 2027 VIRAGE2 data.


Key Events · Earnings and Guidance · TOVX

  • Q3 Loss Narrows to $1.5 Million

    Net loss was $1.5 million, or $0.03 per share, versus $4.4 million, or $0.45 per share, a year earlier; the nine-month loss was $6.7 million versus $21.7 million.

  • Cash Runway Ends Q1 2027

    Cash was $8.5 million at September 30, 2026 and $7.5 million in early November, funding operations only into Q1 2027 — before VIRAGE2 data expected in Q3 2027.

  • Going Concern Doubt Reaffirmed

    Accumulated deficit reached $365.4 million with working capital of $1.8 million; management cites substantial doubt about continuing as a going concern without new capital or a strategic transaction.

  • New Warrant-Vote Lawsuit Disclosed

    Nejmeh v. Theriva Biologics (D. Nev. 3:26-cv-00705) challenges proxy disclosure on the warrant-exercise proposal; a November 18, 2026 special meeting will re-ratify issuance of up to 16,184,560 New Warrant shares and seek authorization of 500,000,000 shares.


Analysis · TOVX · Life Sciences

The Q3 numbers improved — net loss narrowed to $1.5 million from $4.4 million a year earlier, and operating cash burn fell to $8.4 million from $13.8 million — but the balance sheet is the story. Cash stood at $8.5 million on September 30 and $7.5 million in early November, which management says funds operations only into the first quarter of 2027. That is well before the VIRAGE2 Phase 2a data expected in Q3 2027, so the company must raise money or strike a partnership before it can see its own lead readout. The filing also discloses a new Nevada lawsuit over proxy-statement errors on the warrant-exercise vote, and a November 18 special meeting to authorize up to 500 million shares and re-ratify the 16.2 million New Warrant shares — both pointing to further dilution. A $5.0 million deferred Grifols milestone payment would significantly deplete the remaining cash if it comes due.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TOVX was trading at $0.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $0.14 to $0.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TOVX - Latest Insights

TOVX
Nov 12, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.160
Real-time Price: $0.160 info
Change: $0 (0%) info
Market Cap: $7.384M info
TOVX
Nov 02, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1802
Real-time Price: $0.160 info
Change: -$0.0202 (-11%) info
Market Cap: $7.384M info